Literature DB >> 32121328

The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray.

Elisabeth S Gruber1,2, Georg Oberhuber2,3,4, Dietmar Pils2,5, Theresa Stork2,5, Katharina Sinn2,5, Sylvia Gruber2,6, Robert Nica7, Dan Kolmer7, Suzanne D Turner8,9, Michaela Schlederer2,3, Joachim Widder2,6, Wolfgang Doerr2,6, Béla Teleky1,2, Lukas Kenner2,3,10,11,12.   

Abstract

BACKGROUND: T cell density in colorectal cancer (CRC) has proven to be of high prognostic importance. Here, we evaluated the influence of a hyperfractionated preoperative short-term radiation protocol (25 Gy) on immune cell density in tumor samples of rectal cancer (RC) patients and on patient survival. In addition, we assessed spatial tumor heterogeneity by comparison of analogue T cell quantification on full tissue sections with digital T cell quantification on a virtually established tissue microarray (TMA).
METHODS: A total of 75 RC patients (60 irradiated, 15 treatment-naïve) were defined for retrospective analysis. RC samples were processed for immunohistochemistry (CD3, CD8, PD-1, PD-L1). Analogue (score 0-3) as well as digital quantification (TMA: 2 cores vs. 6 cores, mean T cell count) of marker expression in 2 areas (central tumor, CT; invasive margin, IM) was performed. Survival was estimated on the basis of analogue as well as digital marker densities calculated from 2 cores (Immunoscore: CD3/CD8 ratio) and 6 cores per tumor area.
RESULTS: Irradiated RC samples showed a significant decrease in CD3 and CD8 positive T cells, independent of quantification mode. T cell densities of 6 virtual cores approximated to T cell densities of full tissue sections, independent of individual core density or location. Survival analysis based on full tissue section quantification demonstrated that CD3 and CD8 positive T cells as well as PD-1 positive tumor infiltrating leucocytes (TILs) in the CT and the IM had a significant impact on disease-free survival (DFS) as well as overall survival (OS). In addition, CD3 and CD8 positive T cells as well as PD-1 positive TILs in the IM proved as independent prognostic factors for DFS and OS; in the CT, PD-1 positive TILs predicted DFS and CD3 and CD8 positive T cells as well as PD-1 positive TILs predicted OS. Survival analysis based on virtual TMA showed no impact on DFS or OS.
CONCLUSION: Spatial tumor heterogeneity might result in inadequate quantification of immune marker expression; however, if using a TMA, 6 cores per tumor area and patient sample represent comparable amounts of T cell densities to those quantified on full tissue sections. Consistently, the tissue area used for immune marker quantification represents a crucial factor for the evaluation of prognostic and predictive biomarker potential.

Entities:  

Keywords:  Immunoscore; Irradiated rectal cancer; digital pathology; tissue microarray (TMA); virtual microscopy

Year:  2020        PMID: 32121328     DOI: 10.3390/cancers12030563

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  2 in total

Review 1.  Immunity, immunotherapy, and rectal cancer: A clinical and translational science review.

Authors:  Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba
Journal:  Transl Res       Date:  2020-12-08       Impact factor: 7.012

2.  Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome.

Authors:  Shannon M Liudahl; Courtney B Betts; Shamilene Sivagnanam; Jonathan A Nowak; Brian M Wolpin; Lisa M Coussens; Vicente Morales-Oyarvide; Annacarolina da Silva; Chen Yuan; Samuel Hwang; Alison Grossblatt-Wait; Kenna R Leis; William Larson; Meghan B Lavoie; Padraic Robinson; Andressa Dias Costa; Sara A Väyrynen; Thomas E Clancy; Douglas A Rubinson; Jason Link; Dove Keith; Wesley Horton; Margaret A Tempero; Robert H Vonderheide; Elizabeth M Jaffee; Brett Sheppard; Jeremy Goecks; Rosalie C Sears; Byung S Park; Motomi Mori
Journal:  Cancer Discov       Date:  2021-03-16       Impact factor: 39.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.